<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733122</url>
  </required_header>
  <id_info>
    <org_study_id>2008_016</org_study_id>
    <secondary_id>V501-034</secondary_id>
    <nct_id>NCT00733122</nct_id>
  </id_info>
  <brief_title>Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)</brief_title>
  <official_title>Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen&#xD;
      of Gardasil administered to healthy married females between 16 and 23 years of age, in India.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects who seroconvert to each of HPV 6, 11, 16, 18 at Week 4 Post dose 3 (Month 7), Month 24 and Month 36.</measure>
    <time_frame>Week 4 Post dose 3 (Month 7), Month 24 and Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titers (GMTs)</measure>
    <time_frame>Week 4 Post dose 3 (Month 7), Month 24 and Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Married Females Between 16 And 23 Years Of Age With Intact Uteri&#xD;
&#xD;
          -  No Clinical Evidence Of Gross Purulent Cervicitis (Otherwise Postpone Until After&#xD;
             Treatment Or Lack Of Laboratory Confirmation Of Treatable Cause&#xD;
&#xD;
          -  Must Agree To Refrain From Sexual Activity (Including Vaginal And Anal Penetration And&#xD;
             Any Genital Contact) For 48 Hours Prior To Any Scheduled Visit That Includes A Pelvic&#xD;
             Examination In An Attempt To Avoid Detection Of Viral DNA Which Has Been Deposited In&#xD;
             The Vagina Or On The Perineal/Perianal Area During Sexual Intercourse And Is Not The&#xD;
             Result Of Ongoing Infection&#xD;
&#xD;
          -  Not Pregnant Now (As Determined By A Serum Pregnancy Test Or Urine Pregnancy Test&#xD;
             Sensitive To 25 IU/L hCG), And Must Agree To Use Effective Contraception Through Month&#xD;
             7 Of The Study&#xD;
&#xD;
          -  Must Agree To Provide Study Personnel With A Primary Telephone Number As Well As An&#xD;
             Alternate Telephone Number For Follow-Up Purposes.&#xD;
&#xD;
          -  Individuals Who Have Had Sexual Intercourse In The 2 Weeks Prior To Enrollment Must&#xD;
             Have Been Using Effective Contraception As Defined Above (Emergency Contraception Is&#xD;
             Not Considered Effective Contraception For Enrollment Into The Study.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals Concurrently Enrolled In Clinical Studies Of Investigational Agents Or&#xD;
             Studies Involving Collection Of Cervical/Genital Specimens&#xD;
&#xD;
          -  Feverish Feeling Within 24 Hours Prior To The First Injection And No Temperature &lt;&#xD;
             100°F Or &lt; 37.8°C (Oral Or Oral Equivalent) At First Vaccination&#xD;
&#xD;
          -  History Of Recent Or Ongoing Alcohol Or Other Drug Abuse. Alcohol Abusers Are Defined&#xD;
             As Those Who Drink Despite Recurrent Social, Interpersonal, And Legal Problems As A&#xD;
             Result Of Alcohol Use&#xD;
&#xD;
          -  History Of Known Prior Vaccination With An Hpv Vaccine Subject Has Received&#xD;
             Non-Replicating (Inactivated) Vaccine Within 14 Days Prior To The Day 1 Vaccination Or&#xD;
             Has Received Replicating (Live Virus) Vaccine Within 21 Days Prior To The Day 1&#xD;
             Vaccination&#xD;
&#xD;
          -  Individuals With Any Prior Abnormal Pap Test Showing Squamous Intraepithelial Lesion&#xD;
             (Sil), Ascus, Asc-Us, Asc-H Individuals With A History Of Genital Warts&#xD;
&#xD;
          -  Individuals Allergic To Any Vaccine Component, Including Aluminium, Yeast, Or&#xD;
             Benzonase™ (Nuclease, Nycomed [Used To Remove Residual Nucleic Acids From This And&#xD;
             Other Vaccines])&#xD;
&#xD;
          -  Individuals Who Have Received Any Immune Globulin Preparation Or Blood-Derived&#xD;
             Products Within The 3 Months Prior To The First Injection, Or Plan To Receive Any&#xD;
             Through The Completion Of The Study&#xD;
&#xD;
          -  Individuals With A History Of Splenectomy, Known Immune Disorders (E.G., Systemic&#xD;
             Lupus Erythematosus, Rheumatoid Arthritis), Or Receiving Immunosuppressives (E.G.,&#xD;
             Substances Or Treatments Known To Diminish Immune Response Such As Radiation Therapy,&#xD;
             Administration Of Antimetabolites, Antilymphocytic Sera, Systemic Corticosteroids)&#xD;
&#xD;
          -  Individuals Who Have Received Periodic Treatments With Immunosuppressives, Defined As&#xD;
             At Least 3 Courses Of Systemic Corticosteroids Each Lasting At Least 1 Week In&#xD;
             Duration For The Year Prior To Enrollment, Will Be Excluded. Subjects Using Topical&#xD;
             Steroids (I.E., Inhaled Or Nasal) Will Be Eligible For Vaccination&#xD;
&#xD;
          -  Individuals Who Are Immunocompromised Or Have Been Diagnosed As Having HIV Infection&#xD;
&#xD;
          -  Individuals With Known Thrombocytopenia Or Any Coagulation Disorder That Would&#xD;
             Contraindicate Intramuscular Injections&#xD;
&#xD;
          -  Any Condition Which In The Opinion Of The Investigator Might Interfere With The&#xD;
             Evaluation Of The Study Objectives&#xD;
&#xD;
          -  Any Plans To Permanently Relocate From The Area Prior To The Completion Of The Study&#xD;
             Or To Leave For An Extended Period Of Time When Study Visits Would Need To Be&#xD;
             Scheduled&#xD;
&#xD;
          -  Inability To Give Consent/Assent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>January 13, 2011</last_update_submitted>
  <last_update_submitted_qc>January 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vice President of Late Stage Development</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

